Amarin (AMRN) Scheduled to Post Quarterly Earnings on Wednesday

Amarin (NASDAQ:AMRN) will post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Amarin to post earnings of ($0.04) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.04. The business had revenue of $74.71 million for the quarter, compared to analysts’ expectations of $72.46 million. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Stock Performance

Shares of AMRN opened at $0.88 on Tuesday. The business’s fifty day moving average price is $0.97 and its two-hundred day moving average price is $0.94. Amarin has a 52 week low of $0.65 and a 52 week high of $1.49.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amarin has an average rating of “Hold” and an average price target of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.